Global Fibroblast Growth Factors Market Forecast
• Global fibroblast growth factors market size to reach US$500 Mn in 2031, up from around US$280 Mn to be attained in 2024
• Market revenue projected to exhibit a remarkable rate of expansion, at an estimated CAGR of 8.64 % during 2024 - 2031
Quick Report Digest
- The global fibroblast growth factors (FGF) market size will witness more than 1.7x expansion in revenue between 2024 and 2031.
- FGFs find applications in wound healing, tissue regeneration, oncology, and dermatology, with expanding therapeutic potential in cardiovascular diseases and neurological disorders.
- Expansion is fuelled by increasing healthcare expenditure, technological advancements in biotechnology, and expanding applications across various therapeutic areas.
- Regulatory hurdles, safety concerns regarding adverse effects, and limited commercialisation infrastructure pose challenges to market growth.
- Major industry trends include personalised medicine in oncology, collaborative research initiatives, and a shift towards expanded therapeutic applications beyond traditional indications.
- Opportunities lie in exploring novel therapeutic applications and expanding into emerging markets like the Asia Pacific, leveraging growing demand and improving healthcare infrastructure.
- North America leads with established regulatory frameworks and high healthcare expenditure, followed by Europe, and the Asia Pacific, while the Rest of the World shows potential with evolving healthcare infrastructure.
- Major players like Amgen, Pfizer, and Johnson & Johnson dominate the market with continuous R&D efforts, strategic partnerships, and innovative product development.
- Notable developments include Amgen's RegenFibra™ for diabetic foot ulcers, Pfizer's RejuvaGlow™ dermal filler, and Johnson & Johnson's orthopaedic implants distribution agreement.
- Segmented by product type, application areas, end-users, and regions, offering a comprehensive overview of market dynamics and potential growth areas.
A Look Back and a Look Forward - Comparative Analysis
The FGF market has enjoyed a period of steady growth between 2019 and 2023. This expansion can be directly linked to the burgeoning application of FGFs in various fields. In wound healing, these signalling molecules play a vital role in accelerating tissue repair. Regenerative medicine, a field focused on regrowing damaged or diseased tissues, heavily relies on FGFs to stimulate cell growth and differentiation. Even the anti-ageing industry has embraced FGFs for their potential to promote skin health and reduce wrinkles.
During the forecast period, the FGF market is poised to continue its upward trajectory. Several key factors are expected to fuel this growth. The global population is ageing rapidly, leading to a rising demand for treatments that address age-related issues. Public awareness of regenerative medicine techniques is on the rise, creating a larger market for FGF-based therapies. Ongoing research on FGFs holds immense promise for uncovering new applications and improving existing treatments. This continuous innovation is likely to further propel the FGF market forward, solidifying its role in revolutionising healthcare and wellness practices.
Key Growth Determinants
- Expanding Applications
The market is experiencing significant growth due to the expanding applications across various therapeutic areas such as wound healing, tissue regeneration, and oncology. With ongoing research uncovering new potential uses for FGFs in treating a wide range of medical conditions, including cardiovascular diseases and neurological disorders, the market is poised for substantial expansion.
- Technological Advancements
Continuous advancements in biotechnology and genetic engineering are driving innovation in the production and delivery of FGF products. Improved techniques for recombinant protein production, gene therapy, and targeted drug delivery systems are enhancing the efficacy and safety profiles of FGF-based therapies, thereby fuelling market growth.
- Increasing Healthcare Expenditure
Rising healthcare expenditure globally, coupled with growing awareness about the potential benefits of FGF therapies, is contributing to the market's expansion. Governments and healthcare organisations are investing heavily in research and development activities related to FGFs, fostering collaboration between academia, industry, and regulatory bodies to accelerate the development and commercialisation of novel FGF-based treatments. This surge in investment is expected to drive market growth over the forecast period.
Major Growth Barriers
- Regulatory Hurdles
Stringent regulatory requirements for the approval of FGF-based therapies pose a significant restraint on market growth. The complex nature of biological products and the need for rigorous preclinical and clinical testing often result in prolonged approval timelines and high development costs, discouraging investment in FGF research and development.
- Safety Concerns
Despite their therapeutic potential, FGFs may also elicit adverse effects such as tissue overgrowth and tumorigenesis, limiting their clinical utility. Safety concerns associated with FGF-based therapies, including the risk of off-target effects and immune reactions, deter both patients and healthcare providers from adopting these treatments, thereby impeding market expansion.
- Limited Commercialisation Infrastructure
The lack of established infrastructure for the commercialisation and distribution of FGF products presents a significant barrier to market growth. Challenges related to manufacturing scalability, product standardisation, and distribution logistics hinder the widespread availability and accessibility of FGF therapies, particularly in emerging markets, constraining market penetration and revenue generation.
Key Trends and Opportunities to Look at
- The Personalised Medicine Boom
One notable trend in the global fibroblast growth factors market is the shift towards personalised medicine. Advances in molecular profiling techniques, such as genomics and proteomics, enable healthcare providers to tailor treatment strategies based on individual patient characteristics. This trend is particularly relevant in oncology, where FGF-based therapies hold promise for targeted interventions. By identifying specific genetic mutations or biomarkers associated with disease progression, researchers can develop FGF therapies that selectively target tumour cells while minimising off-target effects, thereby improving treatment outcomes and patient satisfaction.
- Collaborative Research Initiatives
Another key trend in the FGF market is the increasing emphasis on collaborative research initiatives among industry players, academic institutions, and government agencies. Recognising the complex nature of FGF biology and the multifaceted challenges associated with developing effective therapies, stakeholders are pooling their resources and expertise to accelerate innovation and streamline the drug development process. Collaborative efforts encompass preclinical research, clinical trials, and regulatory interactions, fostering knowledge exchange and synergistic partnerships that drive scientific discovery and therapeutic advancements in the FGF field.
- Expanded Therapeutic Applications
One of the most significant opportunities for FGF market players lies in exploring and expanding the therapeutic applications of FGF-based therapies beyond traditional indications. While FGFs have demonstrated efficacy in wound healing and tissue regeneration, ongoing research suggests their potential utility in treating a wide range of medical conditions, including cardiovascular diseases, neurological disorders, and metabolic syndromes. By investing in innovative research programs and clinical trials targeting novel disease pathways, companies can unlock new revenue streams and establish a competitive edge in the evolving healthcare landscape.
- Global Market Penetration
Another major opportunity for FGF market players is to capitalize on the growing demand for biopharmaceuticals in emerging markets and underserved regions worldwide. As healthcare infrastructure improves and economic development accelerates in countries such as China, India, and Brazil, there is a burgeoning need for advanced therapeutics to address unmet medical needs. By expanding their market presence and establishing strategic partnerships with local distributors and healthcare providers, FGF manufacturers can tap into these lucrative markets and leverage their product portfolios to drive revenue growth and market expansion on a global scale.
How Does the Regulatory Scenario Shape this Industry?
The regulatory environment significantly impacts the fibroblast growth factors market. Stringent approval processes by agencies like the FDA, involving mandatory clinical trials, can create hurdles for new entrants, potentially slowing down innovation and delaying patient access to these treatments. However, well-defined regulatory pathways for specific FGF applications can expedite approvals, encouraging investment in research and development. Regulations also ensure product quality and safety by setting high standards. Balancing this with fostering innovation is essential, as overly strict regulations can stifle progress, while lax oversight could endanger patients.
Reimbursement policies set by governments and insurance companies significantly affect market growth. Favourable policies can increase market access and adoption, while clear regulations can build trust among patients and healthcare providers, leading to wider acceptance. In conclusion, navigating the regulatory landscape effectively, maintaining high safety standards, and advocating for appropriate reimbursement are crucial for stakeholders to ensure the responsible growth of this promising FGF market.
Fairfield’s Ranking Board
Top Segments
- Wound Healing Applications Represent the Largest Revenue Contributing Area
Wound healing applications represent one of the top-performing segments in the fibroblast growth factors market due to the high demand for effective wound care solutions worldwide. FGFs play a crucial role in promoting tissue repair and regeneration by stimulating fibroblast proliferation, angiogenesis, and extracellular matrix synthesis.
- Orthopaedic Applications Continue to Boast the Top Spot
Orthopaedic applications represent another top-performing segment in the FGF market, fuelled by the rising prevalence of musculoskeletal disorders and the growing demand for regenerative therapies to address orthopaedic injuries and degenerative conditions.
FGFs exhibit potent chondrogenic and osteogenic properties, making them ideal candidates for promoting bone and cartilage regeneration in orthopaedic settings. With an increasing number of orthopaedic surgeries, sports injuries, and age-related musculoskeletal ailments, there is a growing need for innovative FGF-based products, such as bone graft substitutes and growth factor-releasing implants, to facilitate faster and more efficient tissue repair and recovery.
- Dermatology Present a Highly Lucrative Application Area
Dermatological applications emerge as another lucrative segment in the FGF market, driven by the rising prevalence of skin disorders, aesthetic concerns, and the growing demand for anti-ageing solutions. FGFs play a pivotal role in skin regeneration and rejuvenation by stimulating fibroblast proliferation, collagen synthesis, and dermal restructuring.
The increasing consumer awareness about skincare and cosmetic procedures, coupled with advancements in dermatological technologies, fuels the adoption of FGF-based topical formulations, injectables, and medical devices for various dermatological indications, including wound healing, scar revision, and aesthetic enhancement.
Regional Frontrunners
Companies Explore the Most Favourable Growth Environment in North America
The region stands out as a potential frontrunner in the fibroblast growth factors market. This dominance is fuelled by the presence of leading pharmaceutical and biotechnology companies that drive research and development in this field. Additionally, the region boasts a well-established regulatory framework, and high healthcare expenditure, creating a supportive environment for market growth. Further bolstering the market's potential is the rising geriatric population in North America, which translates to a growing demand for treatments that address age-related issues.
Europe, and Asia Pacific Emerge as the Most High-Potential Markets
While Europe presents a compelling market as well, significant government funding will further fuel advancements in healthcare research, fostering innovation in FGF therapies. Public awareness of regenerative medicine techniques is also on the rise in Europe, creating a receptive market for these treatments. However, stringent regulations, while ensuring product safety, may pose a hurdle for new market entrants and slightly slow down market growth.
On the other hand, Asia Pacific holds immense promise due to its rapidly ageing population, particularly in countries like China, and Japan. This demographic shift creates a significant demand for treatments that cater to the needs of the elderly. Rising disposable income in the region further fuels the market's potential as people become more willing to invest in advanced medical treatments. It's important to note that the regulatory landscape in Asia Pacific is still evolving, presenting both challenges and opportunities for future growth.
The rest of the world (RoW) market is also worth considering. Developing countries are increasingly investing in building their healthcare infrastructure, which creates a foundation for future market expansion. Growing interest in FGF therapies is evident in this region as well. However, limitations due to lower overall healthcare spending compared to other regions might exist.
Fairfield’s Competitive Landscape Analysis
The fibroblast growth factors market is fiercely competitive, with leading players such as Amgen Inc., Pfizer Inc., Johnson & Johnson, Novartis AG, and Genentech dominating the landscape. These companies engage in continuous research and development efforts to innovate their product offerings and maintain their competitive edge. Key growth strategies include a strong emphasis on product development, with a focus on creating novel FGF-based therapies that boast enhanced efficacy and safety profiles, often utilising targeted delivery systems.
Strategic partnerships play a crucial role in accelerating innovation, with collaborations between industry giants, academic institutions, and biotechnology firms facilitating access to cutting-edge technologies and expertise. Moreover, companies prioritize market expansion initiatives, both geographically and through the strengthening of distribution networks, to capitalize on emerging opportunities and ensure widespread accessibility to FGF therapies globally.
Who are the Leaders in Global Fibroblast Growth Factors Space?
- Thermo Fisher Scientific
- Sigma-Aldrich (now part of Merck KGaA)
- PeproTech
- R&D Systems (a Bio-Techne brand)
- Abcam
- Cell Signaling Technology
- Novus Biologicals
Significant Company Developments
- June 2023: In June 2023, Amgen Inc. unveiled a groundbreaking FGF-based therapy for diabetic foot ulcers, leveraging advanced tissue engineering techniques to accelerate wound healing and reduce the risk of amputation. The novel product, named RegenFibra™, delivers a potent combination of FGFs and extracellular matrix components to promote tissue regeneration and improve clinical outcomes for patients with chronic wounds.
- October 2023: Pfizer Inc. introduced a pioneering FGF-releasing dermal filler, RejuvaGlow™, in October 2023. This innovative cosmetic product harnesses the regenerative properties of FGFs to stimulate collagen synthesis and rejuvenate ageing skin, offering patients a non-invasive solution for facial rejuvenation and wrinkle reduction.
- March 2024: In March 2024, Johnson & Johnson announced a strategic distribution agreement with a leading biopharmaceutical company to expand the availability of its FGF-based orthopaedic implants in key international markets. This collaboration aims to leverage the partner's established distribution network and market expertise to accelerate the global commercialisation of Johnson & Johnson's innovative orthopaedic products.
An Expert’s Eye
- Expanding Therapeutic Applications: Analysts anticipate a surge in demand for FGF-based therapies across a broad spectrum of therapeutic areas, including wound healing, orthopaedics, dermatology, and oncology. The versatility of FGFs in promoting tissue repair, regeneration, and angiogenesis positions them as promising candidates for addressing unmet medical needs in various disease indications.
- Technological Advancements: Ongoing advancements in biotechnology and regenerative medicine are expected to fuel innovation in FGF research and product development. Novel delivery systems, such as hydrogels, nanoparticles, and gene therapy vectors, enhance the efficacy and targeted delivery of FGFs, expanding their clinical utility and market potential.
- Growing Aging Population: The ageing population, particularly in developed regions, presents a significant market opportunity for FGF-based therapies. Age-related conditions, such as chronic wounds, musculoskeletal disorders, and degenerative diseases, drive the demand for regenerative treatments that can improve quality of life and reduce healthcare burden.
Global fibroblast growth factors market is Segmented as Below:
By Product:
- FGF1
- FGF2
- FGF3
- FGF4
- FGF7
- FGF10
- FGF11
- FGF12
- FGF13
- FGF14
- FGF15
- FGF18
- FGF19
- FGF20
- FGF23
By Application:
- Oncology
- Hematology
- Wound Healing
- Dermatology
- Cardiovascular Disease & Diabetes
- Cell Culture
By End User:
- Pharmaceutical and Biotechnology Companies
- Research Centers & Academic Institutes
- CMO and CDMO
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa (Middle East and Africa)
1. Executive Summary
1.1. Global Fibroblast Growth Factors Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Fibroblast Growth Factors Market Outlook, 2019 - 2031
3.1. Global Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
3.1.1. Key Highlights
3.1.1.1. FGF1
3.1.1.2. FGF2
3.1.1.3. FGF3
3.1.1.4. FGF4
3.1.1.5. FGF7
3.1.1.6. FGF10
3.1.1.7. FGF11
3.1.1.8. FGF12
3.1.1.9. FGF13
3.1.1.10. FGF14
3.1.1.11. FGF15
3.1.1.12. FGF18
3.1.1.13. FGF19
3.1.1.14. FGF20
3.1.1.15. FGF23
3.1.1.16. Others
3.2. Global Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Bn), 2019 - 2031
3.2.1. Key Highlights
3.2.1.1. Oncology
3.2.1.2. Hematology
3.2.1.3. Wound Healing
3.2.1.4. Dermatology
3.2.1.5. Cardiovascular Disease & Diabetes
3.2.1.6. Cell Culture
3.2.1.7. Others
3.3. Global Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
3.3.1. Key Highlights
3.3.1.1. Pharmaceutical & Biotechnology Companies
3.3.1.2. Research Centers & Academic Institutes
3.3.1.3. CMOs & CDMOs
3.4. Global Fibroblast Growth Factors Market Outlook, by Region, Value (US$ Bn), 2019 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Fibroblast Growth Factors Market Outlook, 2019 - 2031
4.1. North America Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
4.1.1. Key Highlights
4.1.1.1. FGF1
4.1.1.2. FGF2
4.1.1.3. FGF3
4.1.1.4. FGF4
4.1.1.5. FGF7
4.1.1.6. FGF10
4.1.1.7. FGF11
4.1.1.8. FGF12
4.1.1.9. FGF13
4.1.1.10. FGF14
4.1.1.11. FGF15
4.1.1.12. FGF18
4.1.1.13. FGF19
4.1.1.14. FGF20
4.1.1.15. FGF23
4.1.1.16. Others
4.2. North America Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Bn), 2019 - 2031
4.2.1. Key Highlights
4.2.1.1. Oncology
4.2.1.2. Hematology
4.2.1.3. Wound Healing
4.2.1.4. Dermatology
4.2.1.5. Cardiovascular Disease & Diabetes
4.2.1.6. Cell Culture
4.2.1.7. Others
4.3. North America Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
4.3.1. Key Highlights
4.3.1.1. Pharmaceutical & Biotechnology Companies
4.3.1.2. Research Centers & Academic Institutes
4.3.1.3. CMOs & CDMOs
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
4.4.1.2. U.S. Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
4.4.1.3. U.S. Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
4.4.1.4. Canada Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
4.4.1.5. Canada Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
4.4.1.6. Canada Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Fibroblast Growth Factors Market Outlook, 2019 - 2031
5.1. Europe Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
5.1.1. Key Highlights
5.1.1.1. FGF1
5.1.1.2. FGF2
5.1.1.3. FGF3
5.1.1.4. FGF4
5.1.1.5. FGF7
5.1.1.6. FGF10
5.1.1.7. FGF11
5.1.1.8. FGF12
5.1.1.9. FGF13
5.1.1.10. FGF14
5.1.1.11. FGF15
5.1.1.12. FGF18
5.1.1.13. FGF19
5.1.1.14. FGF20
5.1.1.15. FGF23
5.1.1.16. Others
5.2. Europe Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Bn), 2019 - 2031
5.2.1. Key Highlights
5.2.1.1. Oncology
5.2.1.2. Hematology
5.2.1.3. Wound Healing
5.2.1.4. Dermatology
5.2.1.5. Cardiovascular Disease & Diabetes
5.2.1.6. Cell Culture
5.2.1.7. Others
5.3. Europe Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
5.3.1. Key Highlights
5.3.1.1. Pharmaceutical & Biotechnology Companies
5.3.1.2. Research Centers & Academic Institutes
5.3.1.3. CMOs & CDMOs
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
5.4.1. Key Highlights
5.4.1.1. Germany Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
5.4.1.2. Germany Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
5.4.1.3. Germany Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
5.4.1.4. U.K. Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
5.4.1.5. U.K. Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
5.4.1.6. U.K. Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
5.4.1.7. France Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
5.4.1.8. France Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
5.4.1.9. France Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
5.4.1.10. Italy Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
5.4.1.11. Italy Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
5.4.1.12. Italy Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
5.4.1.13. Turkey Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
5.4.1.14. Turkey Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
5.4.1.15. Turkey Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
5.4.1.16. Russia Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
5.4.1.17. Russia Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
5.4.1.18. Russia Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
5.4.1.19. Rest of Europe Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
5.4.1.20. Rest of Europe Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
5.4.1.21. Rest of Europe Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Fibroblast Growth Factors Market Outlook, 2019 - 2031
6.1. Asia Pacific Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
6.1.1. Key Highlights
6.1.1.1. FGF1
6.1.1.2. FGF2
6.1.1.3. FGF3
6.1.1.4. FGF4
6.1.1.5. FGF7
6.1.1.6. FGF10
6.1.1.7. FGF11
6.1.1.8. FGF12
6.1.1.9. FGF13
6.1.1.10. FGF14
6.1.1.11. FGF15
6.1.1.12. FGF18
6.1.1.13. FGF19
6.1.1.14. FGF20
6.1.1.15. FGF23
6.1.1.16. Others
6.2. Asia Pacific Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Bn), 2019 - 2031
6.2.1. Key Highlights
6.2.1.1. Oncology
6.2.1.2. Hematology
6.2.1.3. Wound Healing
6.2.1.4. Dermatology
6.2.1.5. Cardiovascular Disease & Diabetes
6.2.1.6. Cell Culture
6.2.1.7. Others
6.3. Asia Pacific Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
6.3.1. Key Highlights
6.3.1.1. Pharmaceutical & Biotechnology Companies
6.3.1.2. Research Centers & Academic Institutes
6.3.1.3. CMOs & CDMOs
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
6.4.1. Key Highlights
6.4.1.1. China Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
6.4.1.2. China Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
6.4.1.3. China Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
6.4.1.4. Japan Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
6.4.1.5. Japan Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
6.4.1.6. Japan Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
6.4.1.7. South Korea Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
6.4.1.8. South Korea Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
6.4.1.9. South Korea Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
6.4.1.10. India Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
6.4.1.11. India Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
6.4.1.12. India Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
6.4.1.13. Southeast Asia Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
6.4.1.14. Southeast Asia Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
6.4.1.15. Southeast Asia Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
6.4.1.16. Rest of Asia Pacific Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
6.4.1.17. Rest of Asia Pacific Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
6.4.1.18. Rest of Asia Pacific Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Fibroblast Growth Factors Market Outlook, 2019 - 2031
7.1. Latin America Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
7.1.1. Key Highlights
7.1.1.1. FGF1
7.1.1.2. FGF2
7.1.1.3. FGF3
7.1.1.4. FGF4
7.1.1.5. FGF7
7.1.1.6. FGF10
7.1.1.7. FGF11
7.1.1.8. FGF12
7.1.1.9. FGF13
7.1.1.10. FGF14
7.1.1.11. FGF15
7.1.1.12. FGF18
7.1.1.13. FGF19
7.1.1.14. FGF20
7.1.1.15. FGF23
7.1.1.16. Others
7.2. Latin America Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Bn), 2019 - 2031
7.2.1. Key Highlights
7.2.1.1. Oncology
7.2.1.2. Hematology
7.2.1.3. Wound Healing
7.2.1.4. Dermatology
7.2.1.5. Cardiovascular Disease & Diabetes
7.2.1.6. Cell Culture
7.2.1.7. Others
7.3. Latin America Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
7.3.1. Key Highlights
7.3.1.1. Pharmaceutical & Biotechnology Companies
7.3.1.2. Research Centers & Academic Institutes
7.3.1.3. CMOs & CDMOs
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
7.4.1.2. Brazil Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
7.4.1.3. Brazil Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
7.4.1.4. Mexico Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
7.4.1.5. Mexico Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
7.4.1.6. Mexico Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
7.4.1.7. Argentina Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
7.4.1.8. Argentina Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
7.4.1.9. Argentina Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
7.4.1.10. Rest of Latin America Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
7.4.1.11. Rest of Latin America Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
7.4.1.12. Rest of Latin America Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Fibroblast Growth Factors Market Outlook, 2019 - 2031
8.1. Middle East & Africa Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
8.1.1. Key Highlights
8.1.1.1. FGF1
8.1.1.2. FGF2
8.1.1.3. FGF3
8.1.1.4. FGF4
8.1.1.5. FGF7
8.1.1.6. FGF10
8.1.1.7. FGF11
8.1.1.8. FGF12
8.1.1.9. FGF13
8.1.1.10. FGF14
8.1.1.11. FGF15
8.1.1.12. FGF18
8.1.1.13. FGF19
8.1.1.14. FGF20
8.1.1.15. FGF23
8.1.1.16. Others
8.2. Middle East & Africa Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Bn), 2019 - 2031
8.2.1. Key Highlights
8.2.1.1. Oncology
8.2.1.2. Hematology
8.2.1.3. Wound Healing
8.2.1.4. Dermatology
8.2.1.5. Cardiovascular Disease & Diabetes
8.2.1.6. Cell Culture
8.2.1.7. Others
8.3. Middle East & Africa Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
8.3.1. Key Highlights
8.3.1.1. Pharmaceutical & Biotechnology Companies
8.3.1.2. Research Centers & Academic Institutes
8.3.1.3. CMOs & CDMOs
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
8.4.1. Key Highlights
8.4.1.1. GCC Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
8.4.1.2. GCC Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
8.4.1.3. GCC Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
8.4.1.4. South Africa Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
8.4.1.5. South Africa Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
8.4.1.6. South Africa Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
8.4.1.7. Egypt Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
8.4.1.8. Egypt Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
8.4.1.9. Egypt Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
8.4.1.10. Nigeria Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
8.4.1.11. Nigeria Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
8.4.1.12. Nigeria Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
8.4.1.13. Rest of Middle East & Africa Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
8.4.1.14. Rest of Middle East & Africa Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
8.4.1.15. Rest of Middle East & Africa Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. By End User vs by Application Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Thermo Fisher Scientific
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Sigma-Aldrich (now part of Merck KGaA)
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. PeproTech
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. R&D Systems (a Bio-Techne brand)
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Abcam
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Cell Signaling Technology
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Novus Biologicals
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations
|
BASE YEAR |
HISTORICAL DATA |
FORECAST PERIOD |
UNITS |
|||
 |
2023 |
 |
2019 - 2023 |
 |
2024 - 2031 |
Value: US$ Million |
|
REPORT FEATURES |
DETAILS |
|
Product Coverage |
|
|
Application Coverage |
|
|
End User Coverage |
|
|
Geographical Coverage |
|
|
Leading Companies |
|
|
Report Highlights |
Key Market Indicators, Macro-micro economic impact analysis, Technological Roadmap, Key Trends, Driver, Restraints, and Future Opportunities & Revenue Pockets, Porter’s 5 Forces Analysis, Historical Trend (2019-2021), Market Estimates and Forecast, Market Dynamics, Industry Trends, Competition Landscape, Category, Region, Country-wise Trends & Analysis, COVID-19 Impact Analysis (Demand and Supply Chain) |
Quality assured
